Nisa Investment Advisors
PACB icon

Nisa Investment Advisors’s Pacific Biosciences PACB Stock Holding History

Nisa Investment Advisors’s Portfolio PACB Stock Details PACB Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$6.12K Hold
3,642
– – ﹤0.01% 2582
2026
Q1 		$4.81K Hold
3,642
– – ﹤0.01% 2463
2025
Q4 		$6.81K Sell
3,642
-2,578
-41% -$4.95K ﹤0.01% 2369
2025
Q3 		$7.96K Hold
6,220
– – ﹤0.01% 2345
2025
Q2 		$7.71K Sell
6,220
-2,421
-28% -$2.8K ﹤0.01% 2359
2025
Q1 		$10.2K Buy
8,641
+7,752
+872% +$11.9K ﹤0.01% 2089
2024
Q4 		$1.63K Sell
889
-9,609
-92% -$18.8K ﹤0.01% 2557
2024
Q3 		$17.8K Buy
10,498
+1,423
+16% +$2.34K ﹤0.01% 1944
2024
Q2 		$12.4K Buy
9,075
+772
+9% +$1.56K ﹤0.01% 2080
2024
Q1 		$31.1K Sell
8,303
-153,955
-95% -$901K ﹤0.01% 1765
2023
Q4 		$1.59M Sell
162,258
-135
-0.1% -$1.1K 0.01% 722
2023
Q3 		$1.36M Buy
162,393
+135
+0.1% +$1.54K 0.01% 784
2023
Q2 		$2.16M Buy
162,258
+540
+0.3% +$6.56K 0.02% 657
2023
Q1 		$1.87M Sell
161,718
-850
-0.5% -$8.45K 0.01% 681
2022
Q4 		$1.33M Hold
162,568
– – 0.01% 836
2022
Q3 		$1.09M Buy
162,568
+153,890
+1,773% +$883K 0.01% 784
2022
Q2 		$38K Buy
8,678
+1,873
+28% +$11.4K ﹤0.01% 1826
2022
Q1 		$62K Buy
6,805
+280
+4% +$3.22K ﹤0.01% 1777
2021
Q4 		$73K Sell
6,525
-677
-9% -$16.3K ﹤0.01% 1621
2021
Q3 		$184K Sell
7,202
-5,291
-42% -$157K ﹤0.01% 1436
2021
Q2 		$437K Hold
12,493
– – ﹤0.01% 1166
2021
Q1 		$416K Sell
12,493
-385
-3% -$13.5K ﹤0.01% 1218
2020
Q4 		$334K Buy
12,878
+4,193
+48% +$71.3K ﹤0.01% 1295
2020
Q3 		$86K Buy
8,685
+6,250
+257% +$36K ﹤0.01% 1589
2020
Q2 		$8K Sell
2,435
-38,685
-94% -$132K ﹤0.01% 1959
2020
Q1 		$126K Buy
41,120
+1,620
+4% +$6.63K ﹤0.01% 1313
2019
Q4 		$203K Hold
39,500
– – ﹤0.01% 1323
2019
Q3 		$204K Buy
+39,500
New +$221K ﹤0.01% 1319
2017
Q1 		– Sell
-1,700
Closed -$6K – 1888
2016
Q4 		$6K Hold
1,700
– – ﹤0.01% 1842
2016
Q3 		$15K Buy
+1,700
New +$14.2K ﹤0.01% 1734

Other funds holding PACB

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
AIM
ARK Investment Management St. Petersburg, Florida $15.4B AUM 50.29% 1-Year Est. Return
SoftBank Group
SoftBank Group Tokyo, Japan $18.2B AUM 177.65% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
Sumitomo Mitsui Trust Group
Sumitomo Mitsui Trust Group Minato-Ku, Tokyo, Japan $175B AUM 40.63% 1-Year Est. Return
NAMA
Nikko Asset Management Americas New York $7.75B AUM 33.73% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return
Point72 Asset Management
Point72 Asset Management Stamford, Connecticut $90.7B AUM 77.13% 1-Year Est. Return
Two Sigma Investments
Two Sigma Investments New York $138B AUM 41.87% 1-Year Est. Return

Nisa Investment Advisors's PACB Position: Q2 2026 in Review

Nisa Investment Advisors held its Pacific Biosciences (PACB) position steady in Q2 2026 at 3,642 shares worth $6.12K. The position accounts for ﹤0.01% of the portfolio, ranked #2582.

Nisa Investment Advisors first reported a position in PACB in Q3 2016 and has held it in 30 quarters since. The position peaked at $2.16M in Q2 2023. 223 funds tracked by Wall St. Rank hold PACB as of Q2 2026.

  • Nisa Investment Advisors held 3,642 shares of Pacific Biosciences worth $6.12K as of Q2 2026.
  • Nisa Investment Advisors left its Pacific Biosciences share count unchanged in Q2 2026.
  • Pacific Biosciences made up ﹤0.01% of Nisa Investment Advisors's portfolio in Q2 2026, its #2582 holding.
  • Nisa Investment Advisors first reported a position in Pacific Biosciences in Q3 2016 and has held it in 30 quarters since.
  • Nisa Investment Advisors's Pacific Biosciences position peaked at $2.16M in Q2 2023.
  • 223 funds tracked by Wall St. Rank held Pacific Biosciences as of Q2 2026.

Based on Nisa Investment Advisors's 13F filing for Q2 2026, filed 10 Aug 2026.